Sibutramine-related panic attack: A clinical case of apparent resolution with paroxetine;Sibutramina e attacco di panico: Un caso clinico con apparente risoluzione mediante paroxetina

Rivista di Psichiatria

Volumn 44, Issue 1, 2009, Pages 64-67

  Fiorentini, Samantha ^a   Russo, Daniele ^a   D'Amato, Antonella ^a   Limpido, Lucilla ^a   Bersani, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Panic disorder; Paroxetine; Sibutramine

Indexed keywords

ALPRAZOLAM; PAROXETINE; SIBUTRAMINE; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGITATION; ARTICLE; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; MUSCLE TONE; NAUSEA; PANIC; PREGNANT WOMAN; TACHYCARDIA; TREATMENT DURATION; TREMOR; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; REMISSION;

ADULT; APPETITE DEPRESSANTS; CYCLOBUTANES; FEMALE; HUMANS; PANIC DISORDER; PAROXETINE; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS;

EID: 77449153187     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: 10.1708/401.4724     Document Type: Article

References (32)

1. Jorge SD, Pobbe RL, de Paula Soares V, de Oliveira AM, Zangrossi H Jr: Effect of sibutramine on anxiety-related behaviour in rats. Pharmacological Research, 2004, 50, 517-522.
2. Buckett WR, Thomas PC, Luscombe GP: The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Progress in Neuropsychopharmacology and Biological Psychiatry, 1988, 12, 575-584.
3. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS: Sibutramine reduces food intake in non-dieting women with obesity. Obesity Research, 1998, 6, 1-11.
4. Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant.The Lancet, 2007, 369, 71-77.
5. Sharma AM, Iacobellis G: Treatment of obesity: a challenging task. Contributions to Nephrology, 2006, 151, 212-220.
6. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC: Sibutramine: a novel anti-obesity drug.A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. International Journal of Obesity and Related Metabolic Disorders, 1998, 22 (suppl 1), S18-S28.
7. Balcioglu A, Wurtman RJ: Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology, 2000, 39, 2352-2359.
8. McNeely W, Goa KL: Sibutramine. A review of its contribution to the management of obesity. Drugs, 1998, 56, 1093-1124.
9. Halford JC, Harrold JA, Lawton CL, Blundell JE: Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Current Drug Targets, 2005, 6, 201-213.
10. Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H: Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Experimental Animals, 2000, 49, 239-249.
11. Deedwania PC, Gupta R: Management issues in the metabolic syndrome. Journal of the Association of Physicians of India, 2006, 54, 797-810.
12. Richardson DK, Jones RB, Bailey CJ: The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. Hormon and Metabolic Research, 2006, 38, 727-731.
13. Schuh LM, Schuster CR, Hopper JA, Mendel CM: Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl), 2000, 147, 339-346.
14. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML: Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. Journal of Clinical Psychopharmacology, 1998, 18, 231-236.
15. Nisoli E, Carruba MO: An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obesity Reviews, 2000, 1, 127-139.
16. Arfken CL, Schuster CR, Johanson CE: Postmarketing surveillance of abuse liability of sibutramine. Drug and Alcohol Dependence, 2003, 69, 169-173.
17. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, et al.: Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clinical Pharmacology and Therapeutics, 2006, 79, 500-508.
18. Shechter M, Beigel R, Freimark D, Matetzky S, Feinberg MS: Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. American Journal of Cardiology, 2006, 97, 1650-1653. Epub 2006 Apr 7.
19. Harrison-Woolrych M, Clark DW, Hill GR, Rees MI, Skinner JR: QT interval prolongation associated with sibutramine treatment. British Journal of Clinical Pharmacology, 2006, 61, 464-469.
20. Baranowska B, Wolinska-Witort E, Martynska L, Chmielowska M, Mazurczak-Pluta T, Boguradzka A, et al.: Sibutramine therapy in obese women: effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinology Letters, 2005, 26, 675-679.
21. Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H: Sibutramine use associated with reversible hepatotoxicity. Annals of Internal Medicine, 2005, 15, 143, 763-764.
22. Lechin F, van der Dijs B, Hernandez G, Orozco B, Rodriguez S, Baez S: Neurochemical, neuroautonomic and neuropharmacological acute effects of sibutramine in healthy subjects. Neurotoxicology, 2006, 27, 184-191. Epub 2005 Nov 2.
23. Benazzi F: Organic hypomania secondary to sibutramine-citalopram interaction. Journal of Clinical Psychiatry, 2002, 63, 165.
24. Cordeiro Q, Vallada H: Sibutramine-induced mania episode in a bipolar patient. International Journal of Neuropsychopharmacology, 2002, 5, 283-284.
25. Taflinski T, Chojnacka J: Sibutramine-associated psychotic episode. American Journal of Psychiatry, 2000, 157, 2057-2058.
26. Binkley K, Knowles SR, Phm SC: Sibutramine and Panic Attack. American Journal of Psychiatry, 2002, 159, 10.
27. Uys JD, Stein DJ, Daniels WM: Neuroproteomics: relevance to anxiety disorders. Current Psychiatry Reports, 2006, 8, 286-290.
28. Max MB, Wu T, Atlas SJ, Edwards RR, Haythornthwaite JA, Bollettino AF, et al.: A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Molecular Pain, 2006, 19, 14.
29. Merikangas KR, Low NC: Genetic epidemiology of anxiety disorders. Handbook of Experimental Pharmacology, 2005, 163-179.
30. Hajduk A: A search for psychobiological determinants of anxiety disorders. Annales Academiae Medicae Stetinensis, 2004, 50, 65-75.
31. Suzuki E, Maruta S: Review of double-blind studies comparing SSRI and SNRI. Seishin Shinkeigaku Zasshi, 2004, 106, 1203-1217.
32. th ed. McGraw-Hill, New York, 1996.